Rico H, Arribas I, Villa L F, Casanova F J, Hernández E R, Cortés-Prieto J
Department of Medicine, Príncipe de Asturias University Hospital, University of Alcalá, Madrid, Spain.
Eur J Clin Invest. 2002 Apr;32(4):274-8. doi: 10.1046/j.1365-2362.2002.00984.x.
A study was carried out over a 24-month interval to determine if an initial measurement of serum tartrate-resistant acid phosphatase would be predictive of bone mass loss quantified by dual-energy X-ray absorptiometry, as total bone mineral content and total bone mineral content corrected for weight.
Sixty-two women were studied (at onset: mean age 59.7 +/- 8.9 years, 10.8 +/- 8.8 years since menopause; at conclusion: mean age 61.9 +/- 8.8 and 13.0 +/- 8.7 since menopause).
A paired Wilcoxon test showed a small, but significant, increase in weight (P < 0.05) and decrease in height (P < 0.05). Total bone mineral content and total bone mineral content corrected for weight decreased (P < 0.005 and 0.0001, respectively). Serum tartrate-resistant acid phosphatase increased (P < 0.005). Single-regression analysis showed that the per cent bone mass loss observed between the first and second body bone mineral content measurements correlated negatively with the first serum tartrate-resistant acid phosphatase determination (r = -0.62, P < 0.0001). Changes in tartrate-resistant acid phosphatase correlated negatively with changes in total bone mineral content (r = -0.79, P < 0.0001). In a multiple regression analysis of per cent change in bone mass against initially important variables such as age, years since menopause, weight, and tartrate-resistant acid phosphatase, only tartrate-resistant acid phosphatase was significant (P < 0.0001). The sensitivity and specifity of tartrate-resistant acid phosphatase for evaluating bone loss were 86% and 78%, respectively, and the area under the curve was of 0.83 (95% CI 0.71-0.95).
These results show that a simple measurement of serum tartrate-resistant acid phosphatase can help to predict the potential rate of bone mass loss in women.
进行了一项为期24个月的研究，以确定血清抗酒石酸酸性磷酸酶的初始测量值是否可预测通过双能X线吸收法量化的骨质流失，即总骨矿物质含量和校正体重后的总骨矿物质含量。
对62名女性进行了研究（开始时：平均年龄59.7±8.9岁，绝经后10.8±8.8年；结束时：平均年龄61.9±8.8岁，绝经后13.0±8.7年）。
配对Wilcoxon检验显示体重有小幅但显著的增加（P<0.05），身高有下降（P<0.05）。总骨矿物质含量和校正体重后的总骨矿物质含量均下降（分别为P<0.005和0.0001）。血清抗酒石酸酸性磷酸酶升高（P<0.005）。单因素回归分析显示，在第一次和第二次身体骨矿物质含量测量之间观察到的骨质流失百分比与第一次血清抗酒石酸酸性磷酸酶测定值呈负相关（r=-0.62，P<0.0001）。抗酒石酸酸性磷酸酶的变化与总骨矿物质含量的变化呈负相关（r=-0.79，P<0.0001）。在对骨质百分比变化与年龄、绝经年限、体重和抗酒石酸酸性磷酸酶等初始重要变量进行的多元回归分析中，只有抗酒石酸酸性磷酸酶具有显著性（P<0.0001）。抗酒石酸酸性磷酸酶评估骨质流失的敏感性和特异性分别为86%和78%，曲线下面积为0.83（95%CI 0.71-0.95）。
这些结果表明，简单测量血清抗酒石酸酸性磷酸酶有助于预测女性骨质流失的潜在速率。
